HalfLifeDBEvidence before certainty.

Dextroamphetamine half-life

The model follows d-amphetamine rather than treating all amphetamine stereoisomers as interchangeable.

Category: stimulant · Updated: August 7, 2026

Sources and model notes are maintained by . This page is educational, not clinical guidance. Corrections: admin@halflifedb.co.

Model status11 hDextroamphetamine · same-day representative value
Reported range10 h–13 hPublished when the current evidence record supports a readable range
Model scopeRelative declineNormalized first-order model, not an in-body concentration estimate
References3Linked studies, labels, reviews, or identity records described below
Relative starting point
100%

Every curve begins at 100%. No dose or measured body concentration is assumed.

0m11h22h33h44h2.3d0%25%50%75%100%X-axis: elapsed timeY-axis: amount remaining (%)

X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. The shaded band shows the reported half-life range. This is a mathematical visualization, not a personal concentration estimate.

Modeled remaining: 50.0%Half-life used: 11 h

Dextroamphetamine: evidence and interpretation notes

What the curve is actually following

The model follows d-amphetamine rather than treating all amphetamine stereoisomers as interchangeable. Labeling shows why urinary pH and formulation can change the apparent elimination pattern.

The visual model centers on Dextroamphetamine at 11 hours. Nothing in the calculation adjusts for dose history, organ function, interactions, tolerance, or a study’s sampling method.

Dextroamphetamine can vary with formulation, route, metabolism, urine pH, and active metabolites. The curve visualizes a selected pharmacokinetic value rather than alertness, cardiovascular effects, sleep disruption, or performance.

What each source contributes

  • DailyMed: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE) CAPSULE [AMNEAL PHARMACEUTICALS OF NEW YORK LLC]. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
  • PubChem: Dextroamphetamine. This identity record confirms names and compound identity and does not supply a human half-life.
  • Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder. This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.

For Dextroamphetamine, the numerical model is tied most closely to DailyMed: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE) CAPSULE [AMNEAL PHARMACEUTICALS OF NEW YORK LLC]. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.

Why the range stays visible

The 10-to-13-hour range is retained beside the 11-hour input for Dextroamphetamine. It is not an uncertainty slider or a personalized prediction; it shows that the cited literature does not reduce to one invariant value.

InterpretationReading the curve and its category context

Reading this curve

HalfLifeDB uses 11 h as a representative input for Dextroamphetamine. In the simplified model, about 22.0% remains after 24 hours and about 3% remains after five half-lives, or roughly 2.3 days.

This sits in the same-day range. The chart is useful for seeing the bend of the curve across a day or two, but it should not be treated as a personal clock. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.

stimulant context

Stimulant half-life estimates can shift with urine pH, enzyme activity, formulation, dose, and whether metabolites are measured separately.

  • Alertness or subjective stimulation can end before modeled elimination.
  • Sleep disruption and downstream effects are not represented by the curve.
  • Formulation and route can change peak timing without changing the displayed model.
ComparisonTimeline checkpoints and nearby profiles

Dextroamphetamine timeline checkpoints

Elapsed timeModeled remainingReading note
12 h46.9%Meaningful modeled decline, not near-zero
24 h22.0%Long-tail portion of the model
2.0 days4.86%Low modeled remainder, not a clearance guarantee
3.0 days1.07%Low modeled remainder, not a clearance guarantee
5.0 days0.05%Low modeled remainder, not a clearance guarantee

Nearby profiles by half-life

These entries sit near Dextroamphetamine within the stimulant group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.

EvidencePharmacokinetic inputs and source trail

Pharmacokinetics at a glance

Representative half-life11 h
Reported range10 h to 13 h
Curve typeNormalized, first-order decline

Selection note: The model follows d-amphetamine rather than treating all amphetamine stereoisomers as interchangeable. Labeling shows why urinary pH and formulation can change the apparent elimination pattern.

Sources and evidence context

A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.

1 PubMed0 PMC1 DailyMed1 PubChem
  1. Official labeling DailyMed label: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE) CAPSULE [AMNEAL PHARMACEUTICALS OF NEW YORK LLC].
    Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
  2. Identity record PubChem Compound Summary: Dextroamphetamine.
    Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
  3. Research abstract PubMed: Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.
    Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
BoundariesWhat this page cannot answer and where to continue

What this page does not answer

  • It does not estimate impairment, intoxication, or fitness to drive.
  • It does not predict urine, blood, saliva, or hair test results.
  • It does not model repeated exposure, tolerance, withdrawal, or interactions.
  • It does not replace clinician, pharmacist, toxicologist, or emergency guidance.

Continue with context

Read the medical disclaimer, methodology, and research standards before using the model for comparison.